We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
- Authors
Poulsen, Hans Skovgaard; Grunnet, Kirsten; Sorensen, Morten; Olsen, Preben; Hasselbalch, Benedikte; Nelausen, Knud; Kosteljanetz, Michael; Lassen, Ulrik
- Abstract
We retrospectively determined the efficacy and safety of a combination of bevacizumab and irinotecan in a consecutive series of 52 heavily pre-treated patients with recurrent high-grade brain tumours. Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) and 125 mg/m(2) for those not receiving EIAEDs] every 2 weeks. Fifty-two patients were included and 47 were evaluable for response.
- Publication
Acta oncologica (Stockholm, Sweden), 2009, Vol 48, Issue 1, p52
- ISSN
1651-226X
- Publication type
Journal Article
- DOI
10.1080/02841860802537924